Oxygen Therapy During Acute Respiratory Failure in Immuno-compromised Patients
Status:
Completed
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
In immunocompromised patients, Acute Respiratory Failure (ARF) is associated with a high
case-fatality, particularly when invasive Mechanical Ventilation (MV) is required. In the
most hypoxemic patients, oxygen administration through High Flow Nasal Cannula (HFNC) has
been reported as an alternative to the venturi mask. The aim of this study is to compare HFNC
and venturi mask on early respiratory deterioration and patient's comfort in that setting.
The investigators planned a prospective randomized study in 4 Intensive Care Units (ICUs). As
respiratory deterioration occurs early after ICU admission, patients are randomized to
receive two hours of oxygen therapy either through HFNC or venturi mask. The primary endpoint
is defined as the need for invasive or noninvasive MV in the 2-hour period. Secondary
endpoints include comfort, dyspnea and thirst.